Journal
EXPERIMENTAL AND MOLECULAR MEDICINE
Volume 42, Issue 10, Pages 675-683Publisher
NATURE PUBLISHING GROUP
DOI: 10.3858/emm.2010.42.10.071
Keywords
antigens, CD86; cell death; graft vs host disease; immunotherapy; T-lymphocytes, regulatory
Funding
- University of Ulsan [2007-0194]
- National Research Foundation of Korea [과06B1212] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Graft-versus-host disease (GVHD) is mediated by mature donor T cells contained in the hematopoietic stem cell graft. During the development of GVHD, signaling through a variety of costimulatory receptors plays an important role in allogeneic T cell responses. Even though delivery of costimulatory signals is a prerequisite for full activation of donor T cells in the phase of their interactions with host APCs, their involvement with GVHD might occur over multiple stages. Like many other aspects of GVHD, promise of therapeutic interventions with costimulatory pathways has been gleaned from preclinical models. In this review, I summarize some of the advances in roles of costimulatory molecules in GVHD pathophysiology and discuss preclinical approaches that warrant further exploration in the clinic, focusing on novel strategies to delete pathogenic T cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available